Quoin Pharmaceuticals receives U.S. patent allowance for Netherton drug

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for U.S. Patent Application No. 18/428,570, titled "Combination Treatment for Netherton Syndrome."

The allowed claims cover a method of treating Netherton Syndrome using a topical serine protease inhibitor, dipalmitoyl hydroxyproline, combined with an anti-inflammatory agent. The claims also include treatment of patients carrying mutations in the SPINK5 gene, the genetic basis of the disease, and cover application to skin lesions on the arms and lower legs. The patent will be formally granted following payment of the issue fee.

The patent relates to QRX003, also known as QYLEKI, Quoin's investigational topical treatment for Netherton Syndrome. The drug holds Orphan Drug, Rare Pediatric Disease, and Fast Track designations from the U.S. Food and Drug Administration, as well as Orphan Drug Designation in the European Union and Japan.

Netherton Syndrome is a rare genetic skin disease caused by SPINK5 mutations, characterized by impaired skin barrier function, persistent inflammation, and increased serine protease activity. There are currently no approved therapies in the United States specifically indicated for the condition.

QRX003 is currently being evaluated in Phase 2 whole-body clinical trials. Quoin has said it expects to initiate a pivotal Phase 3 study in the second half of 2026, with a potential new drug application filing targeted for 2027.

"The allowance of this patent is an important step in protecting the innovation behind our Netherton Syndrome program as we advance toward what could become the first approved treatment for this devastating disease," said Dr. Michael Myers, Co-Founder and Chief Executive Officer of Quoin Pharmaceuticals.

You May Also Be Interested In

• Alphabet taps bond market with sweeping 10-part offering to fuel AI ambitions
• Arbe Robotics names Assaf Pereg as new CFO
• Tarsus Pharmaceuticals raises $125M in oversubscribed PIPE financing